Progenics Pharma (PGNX) Reports Q4 Loss of $0.04/Share
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.04), versus ($0.10) reported last year. Revenue for the quarter came in at $3.9 million, versus $4.65 million reported last year.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Prenetics Global (PRE) Tops Q2 EPS by 18c
- VNET Group (VNET) Misses Q2 EPS by 164c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
